Sign Up for our Newsletter

NIPT
PRENATAL TESTING

Noninvasive prenatal testing for greater accuracy

OVERVIEW

More women deserve the right to NIPT

205973 (132850) cfDNA_Landscape-01

Early answers

Noninvasive prenatal testing (NIPT) consists in analyzing cell-free DNA (cfDNA) circulating in the maternal blood in order to detect fetal chromosomal abnormalities. Testing can be performed as early as 10 weeks of pregnancy.

Molecule of DNA forming inside the test tube equipment.3d rendering,conceptual image.

Safe and accurate

From a simple blood test, NIPT enables safe and early access to reliable results and helps reduce the number of unnecessary invasive procedures.

Close-up Of A Person's Hand Stamping With Approved Stamp On Document At Desk

Global Endorsement

International scientific societies have recognized cell-free DNA testing as the most sensitive and specific screening test for the common fetal aneuploidies, and recommended that it is offered to all pregnant women.1,2

NONINVASIVE PRENATAL TESTING RESOURCES

Expert Insights & Resources

Expand your knowledge with articles, training resources, news & webcasts for professionals and advocates alike.

Minimizing Patients’ Risk of Adverse Outcomes in NIPT
Webinar

Minimizing Patients’ Risk of Adverse Outcomes in NIPT

Lawrence Prensky, MS, LCGC, CCGC, discusses the challenges within NIPT on one of the biggest stages in prenatal health, the CoGEN 2020 World Conference.
Universal access to NIPT: Cost-effective and precise cell-free DNA testing
Webinar

Universal access to NIPT: Cost-effective and precise cell-free DNA testing

This PerkinElmer satellite symposium organized at the European Society of Human Genetics (ESHG) Virtual Conference 2020 presents two laboratories’ experience with Vanadis® NIPT, an automated, non-sequencing cell-free DNA testing platform. Speakers include Dr. Alka Chaubey (PerkinElmer Global Genomic, USA) and Prof. Barbara Pasini (University of Turin, Italy).
Making NIPT accessible to all women
Webinar

Making NIPT accessible to all women

This webinar aims to address some of the obstacles that have prevented the widescale adoption of NIPT. Issues such as: cost, focus, precision and ease of use will all be examined by our speakers and then reevaluated using PerkinElmer's new Vanadis® NIPT platform. Speakers include Prof. Howard Cuckle (Tel Aviv University, Israel) and Dr Alka Chaubey (PerkinElmer Global Genomic, USA)
Implementation and Validation of a High-Precision, Non-NGS NIPT Platform
Webinar

Implementation and Validation of a High-Precision, Non-NGS NIPT Platform

This Genomeweb webinar provides a comprehensive overview of Vanadis® NIPT system, an automated, high-precision non-invasive prenatal testing platform. Speakers: Dr. Glenn Palomaki (Women & Infants Hospital, Rhode Island, USA) and Dr Jérémie Gautier (Cerba Xpert, France).
Variability of “Reported Fetal Fraction” in Noninvasive Prenatal Screening (NIPS)
Peer-reviewed article

Variability of “Reported Fetal Fraction” in Noninvasive Prenatal Screening (NIPS)

Persson et al., Clinical Chemistry, 2021
Prenatal screening for trisomy 21: a comparative performance and cost analysis of different screening strategies
Peer-reviewed article

Prenatal screening for trisomy 21: a comparative performance and cost analysis of different screening strategies

Huang et al., BMC Pregnancy and Childbirth, 2020. Provided by the Springer Nature SharedIt content-sharing initiative. No modifications were made on this material. https://creativecommons.org/licenses/by/4.0/
Clinical validation of a novel automated cell‐free DNA screening assay for trisomies 21, 13, and 18 in maternal plasma
Peer-reviewed article

Clinical validation of a novel automated cell‐free DNA screening assay for trisomies 21, 13, and 18 in maternal plasma

Ericsson et al., Prenatal Diagnosis. 2019
Imaging single DNA molecules for high precision NIPT
Peer-reviewed article

Imaging single DNA molecules for high precision NIPT

Dahl et al., Scientific Reports, 2018
More Resources
TESTING MENU

What You Can Screen For

Common Trisomies

Trisomy 21 (Down syndrome)

Down syndrome, also called trisomy 21, is associated with the presence of an extra copy of chromosome 21. It is the most common chromosomal disorder in liveborn children and, although typically random, does occurs more commonly in the offspring of women as they get older.
Learn More
Common Trisomies

Trisomy 18 (Edwards syndrome)

Edwards syndrome, also called trisomy 18, is a chromosomal disorder associated with the presence of an extra chromosome 18. It is the second most common autosomal trisomy among liveborn children.
Learn More
Common Trisomies

Trisomy 13 (Patau syndrome)

Patau syndrome, also called trisomy 13, is a chromosomal disorder caused by the presence of an extra chromosome 13 in all or some of the cells.
Learn More
SCREENING PLATFORMS

Vanadis® NIPT platform: Built for All

Unlike complex and expensive sequencing-based platforms, Vanadis NIPT enables cost-efficient and high-performance screening for fetal aneuploidies. Making cell-free DNA testing accessible to more laboratories and more women, Vanadis is built for all.

easy

Easy

precise

Precise

cost

Cost-Effective

OUR MOST POPULAR TECHNOLOGY

Featured Products

Vanadis® NIPT system

Vanadis® NIPT system

Fully automated and cost-effective NIPT solution enabling targeted cfDNA analysis with no PCR, no sequencing.
Learn More
LifeCycle™ software

LifeCycle™ software

LifeCycle™ software is the complete data management solution for prenatal screening laboratories
Learn More

Other prenatal screening solutions

shutterstock_364954436

Pre-eclampsia Management

Learn more
Body shot of a pregnant lady with hands on belly

Serum Screening

Learn more
shutterstock_1689772501 1

Sign up for our newsletter

Stay up-to-date on the latest developments related to noninvasive prenatal testing.

Sign Up
GET IN TOUCH

Take the next step

Speak to a salesperson

Talk to one of our product experts about the right solutions for you

Learn More

View more resources

Explore our articles and resources section for the latest information

Learn More

Read the lastest news

Stay up-to-date and peruse our top headlines.

Learn More

References

  1. Practice Bulletin Number 226: Screening for fetal chromosomal abnormalities. Obstet Gynecol. 2020; 136(4)
  2. Benn P, Borrell A, Chiu R, et al. Position statement from the Chromosome Abnormality Screening Committee. Prenat Diagn. 2015;35(8):725-734.

Products may not be licensed in accordance with the laws in all countries, such as the United States and Canada. Please check with your local representative for availability.